title: Pegvisomant: Balance after 10 years.
authors.affiliation: Servicio de Endocrinología y Nutrición, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, España. Electronic address: ignacio.bernabeu.moron@sergas.es.
authors.forename: Ignacio
authors.initials: I
authors.lastname: Bernabeu
authors.affiliation: Servicio de Endocrinología y Nutrición, Hospital Universitario de La Princesa, Madrid, España.
authors.forename: Mónica
authors.initials: M
authors.lastname: Marazuela
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000236:Adenoma / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007016:Hypophysectomy; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D015337:Multicenter Studies as Topic; D064887:Observational Studies as Topic; D011358:Product Surveillance, Postmarketing; D017481:Receptors, Somatostatin / Q000037:antagonists & inhibitors; D047368:Tumor Burden
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017481:Receptors, Somatostatin; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; C406545:pegvisomant